Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Traveler's Diarrhea - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Traveler's Diarrhea - Pipeline Insight, 2024" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Traveler's Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administr ...

Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned for 1H 2025 MELBOURNE, Australia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is p ...

Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the funding of a new research agreement for the Naval Medical Research Command (NMRC), and Walter Reed Army Institute of Research (WRAIR) Silver Spring, MD, USA. The focus of ...

MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on: Thursday 8th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan®) Phase 2 trial and next steps. Following the presentation, attendees will have the opportunity to ask questio ...

Global • FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) • June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter USA • FY 2024 Record sales of AUD$1.1 million up 74% on pcp • June 2024 Quarter AUD$0.3 million up 546% on pcp; down 1% on prior quarter MELBOURNE, Australia, July 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce record sales (unaudited) of Trave ...

MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug Administration (FDA) for IMM-529. The increased incidence of antibiotic resistant 'superbugs' has amplified the use of broad-spectrum antibiotics worldwide. An unintended consequence of antimicrobial treatment is dis ...

Core Viewpoint - Immuron Limited has filed a pre-IND application with the FDA for its investigational drug IMM-529, aimed at addressing Clostridioides difficile infection (CDI) and its associated health threats [1][8]. Industry Context - The rise of antibiotic-resistant 'superbugs' has led to increased use of broad-spectrum antibiotics, which disrupts gastrointestinal microbiota and increases susceptibility to opportunistic pathogens like C. diff [2]. - CDI affects over 400,000 individuals annually in the US, resulting in over 30,000 deaths, highlighting the urgent need for new therapeutics to reduce antibiotic reliance [2]. Company Development - Immuron is collaborating with Monash University to develop IMM-529, which utilizes bovine colostrum-derived antibodies targeting key virulence components of C. diff [3]. - IMM-529 is the only investigational drug showing therapeutic potential across all three phases of CDI [4]. Clinical and Market Potential - IMM-529 is being developed as an adjunctive therapy to standard antibiotics for preventing and treating recurrent CDI, with promising pre-clinical results [8][9]. - The drug targets spores, vegetative cells, and Toxin B of C. diff, with pre-clinical models showing an 80% prevention rate for primary disease and a 67% protection rate against recurrence [9]. - If positioned for second recurrence, approximately 31,000 patients could be eligible, with potential yearly revenue projected at $93 million based on conservative estimates [11]. Technology Platform - Immuron's proprietary technology involves producing polyclonal immunoglobulins from engineered hyper-immune bovine colostrum, which are orally active and can withstand the gastrointestinal environment [13].

MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on June 13th, 2024. Immuron Limited invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Mr. St ...

Core Viewpoint - Immuron Limited, an Australian biopharmaceutical company, is set to present at the Emerging Growth Conference on June 13, 2024, highlighting its innovative products and growth potential [1][4]. Company Overview - Immuron Limited (ASX: IMC; NASDAQ: IMRN) focuses on developing and commercializing orally delivered targeted polyclonal antibodies for treating infectious diseases [7]. - The company’s flagship product, Travelan®, is an orally administered passive immunotherapy that reduces the likelihood of travelers' diarrhea caused by pathogenic bacteria [8][9]. Conference Details - CEO Steven Lydeamore will present for 12 minutes at 2:00 PM US Eastern Standard Time and will address questions from attendees [2]. - The conference aims to connect public companies with individual and institutional investors, showcasing new products and major announcements [4][5]. Product Information - Travelan® is a highly purified tabletized preparation of hyperimmune bovine antibodies that binds to diarrhea-causing bacteria, preventing colonization [8]. - The product is registered in Australia and licensed in Canada, and it is sold as a dietary supplement in the U.S. for digestive tract protection [9]. Technology Platform - Immuron's proprietary technology utilizes polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum, allowing for the development of medicines targeting various infectious diseases [11]. - The platform can produce specific immunoglobulins that remain active in the gastrointestinal tract, effectively neutralizing pathogens [11].

Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [2][3] - The company is listed on both the Australian Securities Exchange (ASX: IMC) and NASDAQ (NASDAQ: IMRN) [2] Product Information - Travelan® is an orally administered passive immunotherapy designed to reduce the likelihood of contracting travelers' diarrhea, which is caused by pathogenic bacteria [3] - Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies that bind to diarrhea-causing bacteria, preventing colonization [3][8] - In Australia, Travelan® is registered as a medicine, while in Canada it is a licensed natural health product, and in the U.S., it is sold as a dietary supplement [3] Technology Platform - Immuron's proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum, allowing for the production of highly specific immunoglobulins to any enteric pathogen [5] - The platform technology enables the development of medicines across a wide range of infectious diseases by blocking viruses or bacteria at mucosal surfaces [5] Research and Development - IMM-124E, developed using Immuron's platform technology, is produced from the colostrum of immunized cattle and contains significant levels of polyclonal antibodies specific for enterotoxigenic E. coli (ETEC) [6][7] - The antibodies in IMM-124E exhibit stronger binding and neutralizing activity against various LPS antigens compared to those from unvaccinated cattle [8]